[Hepatolenticular degeneration: biochemical and therapeutic considerations].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002570:Ceruloplasmin / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use; D003300:Copper / Q000378:metabolism; D004112:Dimercaprol / Q000627:therapeutic use; D004492:Edetic Acid / Q000627:therapeutic use; D006527:Hepatolenticular Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D010396:Penicillamine / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D015032:Zinc / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D002614:Chelating Agents; D004112:Dimercaprol; D003300:Copper; D004492:Edetic Acid; D002570:Ceruloplasmin; D010396:Penicillamine; D015032:Zinc; D011188:Potassium
La degenerazione epatolenticolare: considerazioni biochimiche e terapeutiche